Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca Joins The $35 Club With Cap On Inhaler Copays

Mar 18 2024

• By Alaric DeArment

• Source: Shutterstock

Related Content

Now It’s Asthma Inhalers’ Turn: Boehringer Will Cap Copays, Cut Some List Prices As Pressure Grows

Mar 08 2024

Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale

Mar 02 2023

Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients

Mar 17 2023

The History Behind The Drug-Device Combos Targeted By FTC

Dec 06 2023

AstraZeneca Outlines Growth Ambitions – Could This Include Oncology Leadership By 2030?

Feb 08 2024

Related Companies

Boehringer Ingelheim GmbH

AstraZeneca PLC

GSK plc

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

Novo Nordisk A/S

Sanofi

Additional Topics

Pricing Debate Pricing Strategies Commercial Respiratory BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window